Cited by 265Metabolism and Genetic DisordersAmino Acid Enzymes and MetabolismNeonatal Health and Biochemistry

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Holme, E., Lindstedt, S.·1998·Journal of Inherited Metabolic Disease

DOI 10.1023/a:1005410820201

Open this paper in CoChat — free account

Abstract

In tyrosinaemia type I (McKusick 276700), fatal liver disease results either because of liver failure during infancy or early childhood or because of development of hepatocellular carcinoma during childhood or adolescence. This is caused by toxic metabolites which accumulate because of deficiency of fumarylacetoacetase, the last enzyme in the tyrosine catabolic pathway. NTBC is a potent inhibitor of 4‐hydroxyphenylpyruvate dioxygenase and has been shown to efficiently prevent tyrosine degradation, and production of succinylacetone, in patients with tyrosinaemia. Since the first trial of NTBC treatment for tyrosinaemia type I in 1991, over 220 patients have been treated by the drug using a protocol which includes regular follow‐up with reports of clinical and laboratory investigations to the study centre in Gothenburg, where additional analysis of critical variables is done on regularly collected samples. The course of the disease in patients with acute tyrosinaemia has changed dramatically. Only 10% of the patients have not clinically responded to NTBC treatment. In half of these patients, successful liver transplantation has been performed which has further reduced the mortality rate during infancy to 5%. The international NTBC study has now been going for 5 years and data have emerged that indicate a decreased risk for early development of hepatocellular carcinoma in patients who started treatment at an early age. There are now 101 patients aged 2–8 years who have started NTBC treatment before 2 years of age, and no cancer has developed after 2 years of age among these patients. However, there is no safe age with respect to occurrence of liver cancer, which has been recognized at diagnosis at 1 year of age in one patient and after a few months of treatment in an infant who was given NTBC at 5 months of age.

Integrity signals

Registry

Crossref · 10.1023/a:1005410820201

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Self-citation
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Self-citation
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312
Self-citation
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G. A., Larochelle, J., Lambert, M. A., Michaud, J., Grenier, A., de Baulny, H. O., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 230
Hereditary Tyrosinemia Type I: A New Clinical Classification With Difference in Prognosis on Dietary Treatment
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione
Ellis, M. K., Whitfield, A. C., Gowans, L. A., Auton, T. R., Provan, W. M., Lock, E. A., & Smith, L. L. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1121 · Cited by 114
From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 2×
“In older patients, the low production may in part be due to self-induced correction of the fumarylacetoacetase defect (Kvittingen et al 1993, 1994), which has been documented to occur in nodules of regenerative liver tissue.”
Background

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 5

Dionisi‐Vici C, 1997, Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal, J Inher Metab Dis, 20, 15
Holme E, 1995, Treatment of tyrosinemia type I with an enzyme inhibitor, Int Pediatr, 10, 41
Kerckaert I, 1997, Secondary alterations of hepatic peroxisomes in tyrosinaemia type I: morphometry and electron microscopy, J Inher Metab Dis, 20, 13
Segel I, 1975, Enzyme Kinetics
Vilaseca MA, 1997, Chronic form of tyrosinaemia type I: late‐onset treatment with NTBC, J Inher Metab Dis, 20, 10

Sorted by citations

Items 101–200 of 265

EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?
Schmidt, L., Sehic, O., & Wild, C. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00317-8 · Cited by 26
Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia
Rashed, M. S., Al-Ahaidib, L. Y., Al-Dirbashi, O. Y., Amoudi, M. A., Al‐Sayed, M., Rahbeeni, Z. A., Al‐Hassnan, Z. N., Al-Dbaas, A., Al‐Owain, M., & Luanaigh, M. N. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.01.014 · Cited by 25
Lectin‐reactive α‐Fetoprotein in Patients with Tyrosinemia Type I and Hepatocellular Carcinoma
Baumann, U., Duhme, V., Auth, M. K. H., McKiernan, P. J., & Holme, E. (2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000228112.29359.f8 · Cited by 25
Self-citation
Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
Couce, M. L., Sánchez‐Pintos, P., Aldamiz-Echevarria, L. J., Vitoria, I., Navas, V., Martín‐Hernández, E., García‐Volpe, C., Pintos‐Morell, G., Quintana, L. P., Bertó, T. H., et al. (2019) · Medicine · doi:10.1097/md.0000000000017303 · Cited by 25
Toxic Metabolites and Inborn Errors of Amino Acid Metabolism: What One Informs about the Other
Lee, N., & Kim, D. (2022) · Metabolites · doi:10.3390/metabo12060527 · Cited by 26
Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography–tandem mass spectrometry. Study of the stability of the samples at different temperatures
Prieto, J. A., Andrade, F., Lage, S., & Aldamiz-Echevarria, L. J. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.01.031 · Cited by 24
Manifestation of hawkinsinuria in a patient compound heterozygous for hawkinsinuria and tyrosinemia III
Item, C. B., Mihalek, I., Lichtarge, O., Jalan, A., Vodopiutz, J., Mühl, A., & Bodamer, O. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.04.008 · Cited by 24
Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I
André, N., Roquelaure, B., Jubin, V., & Ovaert, C. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-5085-4 · Cited by 23
Hereditary tyrosinaemia type I in Norway: Incidence and three novel small deletions in the fumarylacetoacetase gene
Bliksrud, Y. T., Brodtkorb, E., Backe, P. H., Woldseth, B., & Rootwelt, H. (2012) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.676210 · Cited by 23
Chapter 33. To market, to market - 2002
Boyer-Joubert, C., Lorthiois, E., & Moreau, F. (2003) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(03)38034-0 · Cited by 23
Newborn screening for Tyr-I: Two years' experience of the New York State program
Morrissey, M. A., Sunny, S., Fahim, A., Lubowski, C., & Caggana, M. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.02.017 · Cited by 22
Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin
Imtiaz, F., Rashed, M. S., Al-Mubarak, B. R., Allam, R., El-Karaksy, H. M., Al‐Hassnan, Z. N., Al‐Owain, M. A., Alzaidan, H., Rahbeeni, Z. A., Qari, A., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.019 · Cited by 22
Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases
El-Karaksy, H. M., Fahmy, M. E., El‐Raziky, M. S., El-Koofy, N. M., El‐Sayed, R., Rashed, M. S., El-Kiki, H., El-Hennawy, A., & Mohsen, N. (2011) · World Journal of Pediatrics · doi:10.1007/s12519-011-0287-3 · Cited by 21
The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: Clinical and laboratory findings of five cases
Büyükpamukçu, M., Varan, A., Haberal, M. A., Büyükpamukçu, N., Köksal, Y., Coşkun, T., Yüce, A., Kale, G., Akyüz, C., & Kutluk, T. (2006) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2006.00511.x · Cited by 21
Mechanisms of Liver Injury Relevant to Pediatric Hepatology
Tanner, M. S. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795439 · Cited by 20
Hereditary tyrosinaemia type I: from basics to progress in treatment
Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2000) · Annals of Medicine · doi:10.3109/07853890008998832 · Cited by 20
CURRENT STATUS OF PEDIATRIC LIVER TRANSPLANTATION
Abramson, O., & Rosenthal, P. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70125-2 · Cited by 19
Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day
Kienstra, N. S., van Reemst, H. E., van Ginkel, W. G., Daly, A., van Dam, E., MacDonald, A., Burgerhof, J. G. M., de Blaauw, P., McKiernan, P. J., Heiner-Fokkema, M. R., et al. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0112-9 · Cited by 19
Type 1 tyrosinemia in Finland: a nationwide study
Aitokari, L., Hiltunen, P., Soini, T., Vuorela, N., Huhtala, H., Nevalainen, P. I., Heikinheimo, M., Kivelä, L., & Kurppa, K. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01547-w · Cited by 20
Hepatic Tumors in Childhood
Finegold, M. J., & Lopez-Terrada, D. H. (2014) · Springer eBooks · doi:10.1007/978-3-642-54053-0_14 · Cited by 19
Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria
Gertsman, I., Barshop, B. A., Panyard-Davis, J. L., Gangoiti, J. A., & Nyhan, W. L. (2015) · JIMD Reports · doi:10.1007/8904_2014_403 · Cited by 18
Determination of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in plasma by direct injection into a coupled column liquid chromatographic system
Bielenstein, M., Astner, L., & Ekberg, S. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00199-1 · Cited by 18
Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine
Metz, T. F., Mechtler, T. P., Merk, M., Gottschalk, A., Lukačin, R., Herkner, K. R., & Kasper, D. C. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.04.007 · Cited by 18
Kidneys of Mice With Hereditary Tyrosinemia Type I Are Extremely Sensitive to Cytotoxicity
Jacobs, S. M. M., van Beurden, D., Klomp, L. W. J., Berger, R., & van den Berg, I. E. T. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000198810.57642.b4 · Cited by 16
Confocal Microscopy of Corneal Crystals in a Patient With Hereditary Tyrosinemia Type I, Treated With NTBC
Schauwvlieghe, P., Jaeken, J., Kestelyn, P., & Claerhout, I. (2012) · Cornea · doi:10.1097/ico.0b013e318243e474 · Cited by 16
Hepatic Neoplasia and Metabolic Diseases in Children
Roy, A., & Finegold, M. J. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.07.002 · Cited by 16
The different catalytic roles of the metal-binding ligands in human 4-hydroxyphenylpyruvate dioxygenase
Huang, C.-W., Liu, H.-C., Shen, C.-P., Chen, Y.-T., Lee, S.-J., Lloyd, M. D., & Lee, H. (2016) · Biochemical Journal · doi:10.1042/bcj20160146 · Cited by 16
Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders
Burns, T. M., Ryan, M. M., Darras, B. T., & Jones, H. R. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.7.858 · Cited by 16
Diagnosis and early management of inborn errors of metabolism presenting around the time of birth
Leonard, J. V., & Morris, A. A. M. (2006) · Acta Paediatrica · doi:10.1111/j.1651-2227.2006.tb02172.x · Cited by 16
Simple and Fast Quantification of Nitisone (NTBC) using Liquid Chromatography-Tandem Mass Spectrometry Method in Plasma of Tyrosinemia Type 1 Patients
Spraul, A., Romdhane, H. B., & Poggi-Bach, J. (2012) · Journal of Chromatographic Science · doi:10.1093/chromsci/bms022 · Cited by 15
A False-Negative Newborn Screen for Tyrosinemia Type 1—Need for Re-Evaluation of Newborn Screening with Succinylacetone
Dijkstra, A. M., van Vliet, K., Heiner-Fokkema, M. R., Bodewes, F. A. J. A., Bos, D. K., Zsíros, J., van Aerde, K., Koop, K., van Spronsen, F. J., & Lubout, C. M. A. (2023) · International Journal of Neonatal Screening · doi:10.3390/ijns9040066 · Cited by 14
Neurocognitive outcome and mental health in children with tyrosinemia type 1 and phenylketonuria: A comparison between two genetic disorders affecting the same metabolic pathway
van Vliet, K., van Ginkel, W. G., Jahja, R., Daly, A., MacDonald, A., Santra, S., Laet, C. D., Goyens, P. J., Vara, R., Rahman, Y., et al. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12528 · Cited by 14
High volume naked DNA tail‐vein injection restores liver function in Fah‐knock out mice
Eggenhofer, E., Doenecke, A., Renner, P., Slowik, P., Piso, P., Geissler, E. K., Schlitt, H. J., Dahlke, M. H., & Popp, F. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06156.x · Cited by 15
Liver Diseases
Dhillon, A., & Steadman, R. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2787-6.00005-x · Cited by 14
Developmental and Inherited Liver Disease
Quaglia, A., Roberts, E. A., & Torbenson, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00003-0 · Cited by 14
Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1
Schlump, J.-U., Mayatepek, E., & Spiekerkoetter, U. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1074-1 · Cited by 13
Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation
Joshi, S. N., & Venugopalan, P. (2004) · Annals of Tropical Paediatrics · doi:10.1179/027249304225019000 · Cited by 13
Preliminary Proficiency Testing Results for Succinylacetone in Dried Blood Spots for Newborn Screening for Tyrosinemia Type I
Adam, B. W., Lim, T. H., Hall, E. M., & Hannon, W. H. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.133819 · Cited by 12
Pharmacotherapy of inborn errors of metabolism illustrating challenges in orphan diseases
Das, A. M. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.02.182 · Cited by 12
The outcome of seven patients with hereditary tyrosinemia type 1
Gökay, S., Üstkoyuncu, P. S., Kardaş, F., & Kendırcı, M. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0471 · Cited by 12
Hereditary Tyrosinemia Type 1 in Turkey
Zeybek, A. Ç. A., Kıykım, E., & Cansever, M. Ş. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_15 · Cited by 12
Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
Jack, R. M., & Scott, C. R. (2019) · JIMD Reports · doi:10.1002/jmd2.12023 · Cited by 12
Tyrosine Metabolism
Holme, E., & Mitchell, G. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-40337-8_2 · Cited by 12
Self-citation
Tyrosinemia type I: A clinico-laboratory case report
Karnik, D., Thomas, N., Eapen, C. E., Jana, A. K., & Oommen, A. M. (2004) · The Indian Journal of Pediatrics · doi:10.1007/bf02830839 · Cited by 12
Treatment: Present Status and New Trends
Walter, J. H., & Wraith, J. E. (2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8_5 · Cited by 11
CRISPR-Based Tools for Fighting Rare Diseases
Li, Q., Gao, Y., & Wang, H. (2022) · Life · doi:10.3390/life12121968 · Cited by 11
Gene therapy for liver enzyme deficiencies: what have we learned from models for Crigler–Najjar and tyrosinemia?
Nguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 11
Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
van Ginkel, W. G., van Vliet, D., Burgerhof, J. G. M., de Blaauw, P., Rubio‐Gozalbo, M. E., Heiner-Fokkema, M. R., & van Spronsen, F. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185342 · Cited by 11
The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients
van Ginkel, W. G., van Reemst, H. E., Kienstra, N. S., Daly, A., Rodenburg, I. L., MacDonald, A., Burgerhof, J. G. M., de Blaauw, P., van der Krogt, J., Santra, S., et al. (2019) · Nutrients · doi:10.3390/nu11112816 · Cited by 11
Triketone toxicity
Boels, D., Monteil‐Ganière, C., Turcant, A., Bretaudeau, M., & Harry, P. (2013) · Human & Experimental Toxicology · doi:10.1177/0960327112468908 · Cited by 11
Role of the tyrosine aminotransferase AccTATN gene in the response to pesticide and heavy metal stress in Apis cerana cerana
Sun, Y.-H., Niu, X.-J., Huang, Y., Wang, L., Liu, Z., Guo, X., Xu, B., & Wang, C. (2023) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2023.105372 · Cited by 10
Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
Norman, B. P., Davison, A. S., Hickton, B., Ross, G. A., Milan, A. M., Hughes, A. T., Wilson, P. J. M., Sutherland, H., Hughes, J. H., Roberts, N. B., et al. (2022) · Metabolites · doi:10.3390/metabo12100927 · Cited by 10
Characterization of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione resistance in pyomelanogenic Pseudomonas aeruginosa DKN343
Ketelboeter, L. M., & Bardy, S. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178084 · Cited by 10
Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1
Langlois, C., Jorquera, R., Finegold, M. J., Shroads, A. L., Stacpoole, P. W., & Tanguay, R. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.017 · Cited by 11
HEPATOCYTE TRANSPLANTATION
Ng, V. L., Alonso, M., & Bezerra, J. A. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70147-1 · Cited by 10
Functional role of residues involved in substrate binding of human 4-hydroxyphenylpyruvate dioxygenase
Huang, C.-W., Hwang, C., Chang, Y., Liu, J., Wu, S.-P., Huang, K., Huang, W., & Lee, H. (2021) · Biochemical Journal · doi:10.1042/bcj20210005 · Cited by 9
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
Priestley, J. R. C., Alharbi, H., Callahan, K. P., Guzman, H., Payan‐Walters, I., Smith, L., Ficicioglu, C. H., Ganetzky, R. D., & Ahrens‐Nicklas, R. C. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6020039 · Cited by 10
Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients
Karaca, C. A., Yılmaz, H., Farajov, R., Iakobadze, Z., Aydoğdu, S., & Kılıç, M. (2019) · Pediatric Transplantation · doi:10.1111/petr.13498 · Cited by 9
Amino Acid Metabolism
Wang, R., Wilcox, W. R., & Cederbaum, S. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00096-3 · Cited by 9
Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]- cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy.
Szczeciński, P., Lamparska, D., Gryff‐Keller, A., & Gradowska, W. (2008) · Acta Biochimica Polonica · doi:10.18388/abp.2008_3036 · Cited by 9
Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended
D’Eufemia, P., Celli, M., Tetti, M., & Finocchiaro, R. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1419-4 · Cited by 9
Infiltrating neutrophils aggravate metabolic liver failure in fah‐deficient mice
Qi, Z., Wang, X., Wei, H., Sun, R., & Tian, Z. (2014) · Liver International · doi:10.1111/liv.12594 · Cited by 8
Effects of a protein‐restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria
Olsson, B., Ranganath, L. R., Arnoux, J., Imrich, R., Milan, A. M., & Rudebeck, M. (2021) · JIMD Reports · doi:10.1002/jmd2.12255 · Cited by 7
Hepatocellular Carcinoma in Hereditary Tyrosinemia Type I Despite 2‐(2 Nitro‐4‐3 Trifluoro‐ Methylbenzoyl)‐1, 3‐Cyclohexanedione Treatment
van Spronsen, F. J., Bijleveld, C. M. A., van Maldegem, B. T., & Wijburg, F. A. (2005) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2005.tb00933.x · Cited by 8
Evolución de un caso de tirosinemia crónica tipo I tratado con NTBC
Viladoms, J. R., Buscà, M. A. V., Ferri, N. L., Comas, A., Pascual, E. G., & Holme, E. (2001) · Anales de Pediatría · doi:10.1016/s1695-4033(01)77531-5 · Cited by 9
Self-citation
Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1
Luijerink, M., van Beurden, E. A. C. M., Malingré, H. E. M., Jacobs, S. M. M., Grompe, M., Klomp, L. W. J., Berger, R., & van den Berg, I. E. T. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00788.x · Cited by 8
Hepatic Tumors in Childhood
Finegold, M. J. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9066-2_13 · Cited by 8
NTBC as palliative treatment in chronic tyrosinaemia type I
Ros, J., Vilaseca, M., Lambruschini, N., Mas, A., Lindstedt, S., & Holme, E. (1999) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005594416973 · Cited by 7
Self-citation
Tissue-specific FAH deficiency alters sleep–wake patterns and results in chronic tyrosinemia in mice
Yang, S., Siepka, S. M., Cox, K. H., Kumar, V., de Groot, M. H. M., Chelliah, Y., Chen, J., Tu, B. P., & Takahashi, J. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904485116 · Cited by 6
NTBC Treatment Monitoring in Chilean Patients with Tyrosinemia Type 1 and Its Association with Biochemical Parameters and Liver Biomarkers
Fuenzalida, K. M., Leal-Witt, M. J., Guerrero, P., Hamilton, V., V, Salazar, M. F., Peñaloza, F., Arias, C., & Cornejo, V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245832 · Cited by 6
Corneal Pseudodendritic Lesions Masquerading as Herpetic Keratitis in a Patient With Tyrosinemia Type I
Sevim, D. G., Gümüş, K., & Cavanagh, H. D. (2015) · Eye & Contact Lens Science & Clinical Practice · doi:10.1097/icl.0000000000000187 · Cited by 6
Tyrosinemia I, A Model For Human Diseases Mediated By 2-Oxoacid-Utilizing Dioxygenases: Hepatotoxin Suppression By NTBC Does Not Normalize Hepatic Collagen Metabolism
Hanauske-Abel, H. M., Popowicz, A. M., Remotti, H. E., Newfield, R. S., & Levy, J. F. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200207000-00016 · Cited by 6
Fanconi Syndrome
Böckenhauer, D., & Hoff, W. V. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04883-5.50034-9 · Cited by 6
Disorders of Tyrosine Metabolism
Kvittingen, E. A., & Holme, E. (2000) · Springer eBooks · doi:10.1007/978-3-662-04285-4_15 · Cited by 6
Self-citation
General and Theoretical Aspects of the Metal Enolates
Domingo, L. R., & Andrés, J. (2010) · Patai's chemistry of functional groups · doi:10.1002/9780470682531.pat0417 · Cited by 6
Enhancing Newborn Screening for Tyrosinemia Type I
Pass, K. A., & Morrissey, M. A. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.103200 · Cited by 6
Disorders of Tyrosine Degradation
Holme, E. (2006) · Physician’s Guide to the Treatment and Follow-Up of Metabolic Diseases · doi:10.1007/3-540-28962-3_6 · Cited by 5
Self-citation
Nonintegrating Direct Conversion Using mRNA into Hepatocyte-Like Cells
Yoon, S., Kang, K., Cho, Y., Kim, Y., Buisson, E. M., Yim, J.-H., Lee, S. B., Ryu, K., Jeong, J., & Choi, D. (2018) · BioMed Research International · doi:10.1155/2018/8240567 · Cited by 4
Identification and antioxidant capacity of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a new favored herbicide target, in Apis cerana cerana
Gong, X., Zhao, G., Shan, W., Guo, H., Wang, C., Liu, Q., Xu, B., Wang, Y., & Guo, X. (2022) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2022.105110 · Cited by 5
Principles of management of the more common metabolic disorders
Chakrapani, A., & Wraith, J. E. (2002) · Current Paediatrics · doi:10.1054/cupe.2001.0262 · Cited by 5
NMR and computational studies on tautomerism of 3-hydroxy-2-(2-thienylcarbonyl)cyclohex-2-en-1-one
Chans, G. M., Moyano, E. L., & Baumgartner, M. T. (2013) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2013.11.057 · Cited by 5
Developmental and Inherited Liver Disease
Quaglia, A., Roberts, E. A., & Torbenson, M. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00003-x · Cited by 5
Novel Synthesis of 2-thienylcarbonyl-cyclohexane-1,3-dione as Building Block for Indazolones and Isoxazolones
Chans, G. M., Moyano, E. L., & Yranzo, G. I. (2011) · Australian Journal of Chemistry · doi:10.1071/ch11015 · Cited by 5
General Criteria for Pediatric Transplantation
Alonso, E. M., Besedovsky, A., Emerick, K. M., & Whitington, P. F. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0118-2.50026-4 · Cited by 5
Tyrosinemia Typel: A case report.
Rashad, M. M., & Nassar, C. (2011) · Europe PMC (PubMed Central) · Cited by 5
Hepatorenal Tyrosinemia
Tanguay, R. M., Bergeron, A., & Jorquera, R. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-449851-8.00040-1 · Cited by 5
Amino Acid Metabolism
Russo, R. S., & Wilcox, W. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00003-0 · Cited by 4
Ocular Manifestations of Inborn Errors of Metabolism
Ganesh, A., Al-Murshedi, F., Al-Zuhaibi, S. S., & Al‐Thihli, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-18389-3_13 · Cited by 5
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasisPreprint
Sterkel, M., Haines, L. R., Casas-Sánchez, A., Adung’a, V. O., Vionette-Amaral, R. J., Quek, S., Rose, C., dos Santos, M. S., Escude, N. G., Ismail, H. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.08.139808 · Cited by 4
Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines
Dijkstra, A. M., Das, A. M., Maiorana, A., Heiner-Fokkema, M. R., & van Spronsen, F. J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70089 · Cited by 6
Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study
Fuenzalida, K. M., Leal-Witt, M. J., Acevedo, A., Muñoz, M., Gudenschwager, C., Arias, C., Cabello, J. F., la Marca, G., Rizzo, C., Pietrobattista, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083839 · Cited by 3
New Innovations: Therapies for Genetic Conditions
Rajabi, F., & Picker, J. D. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0043-9 · Cited by 4
Renal Fanconi Syndromes and Other Proximal Tubular Disorders
Böckenhauer, D., & Kleta, R. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_32 · Cited by 3
Tyrosine Metabolism
van Spronsen, F. J., Burlina, A., & Dionisi‐Vici, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-67727-5_21 · Cited by 3
Metabolic Disease and Hepatocellular Carcinoma
Thiel, D. H. V., & Ramadori, G. P. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-376-3_9 · Cited by 3
Disorders of Tyrosine Degradation
Holme, E. (2003) · Springer eBooks · doi:10.1007/978-3-642-55878-8_10 · Cited by 3
Self-citation
Peripheral Neuropathy in Inherited Metabolic Disease
Patterson, M. C., & Percy, A. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00019-6 · Cited by 4
Disorders of Amino Acid Metabolism, Organic Acidaemias and Urea Cycle Defects
Dixon, M. (2001) · doi:10.1002/9780470690369.ch15 · Cited by 3
Crisis neuropática por suspensión de nitisinona en una paciente con tirosinemia: informe de un caso
Ibarra‐González, I., Belmont‐Martínez, L., Cervantes‐Bustamante, R., Zárate-Mondragón, F. E., López, S. G., Fernández‐Lainez, C., Revilla-Estivil, N., & Vela-Amieva, M. B. (2017) · Acta Pediátrica de México · doi:10.18233/apm38no5pp322-3291472 · Cited by 2
A journey of hope: lessons learned from studies on rare diseases and orphan drugs
Astfelt, M. W. (2006) · Cited by 2

Authors: Holme, E., & Lindstedt, S.
Affiliations: Sahlgrenska University Hospital (SE)
Venue: Journal of Inherited Metabolic Disease
Publisher: Wiley
Published: 1998-08
Volume: 21
Issue: 5
Pages: 507-517
ISSN: 0141-8955 (ISSN-L)
1573-2665
DOI: 10.1023/a:1005410820201
OpenAlex: W1567009066
Cited by: 264
References: 17
Citations by year: 2026: 1 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 10 · 2018: 2 · 2017: 18 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 11 · 2012: 7
FWCI: 5.92
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Inherited Metabolic Disease (publishedVersion)
PubMed (publishedVersion)
Funders: Swedish Cancer Foundation
Vetenskapsrådet
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords: NTBC, tyrosine catabolism, hepatocellular carcinoma prevention, liver transplantation, succinylacetone, early treatment initiation, treatment response
MeSH terms: Amino Acid Metabolism, Inborn Errors, Animals, Clinical Trials as Topic, Cyclohexanones, Enzyme Inhibitors, Humans, Nitrobenzoates, Tyrosine, 4-Hydroxyphenylpyruvate Dioxygenase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks